LCO 1 of 2
General Assembly Substitute Bill No. 241
February Session, 2024
AN ACT CONCERNING THE OFFICE OF HEALTH STRATEGY'S
RECOMMENDATIONS REGARDING 340B PROGRAM
TRANSPARENCY.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
Section 1. (NEW) (Effective October 1, 2024) (a) As used in this section, 1
(1) "federal 340B Drug Pricing Program" or "program" means the plan 2
described in Section 340B of the Public Health Service Act, 42 USC 256b, 3
as amended from time to time, and (2) "340B covered entity" means an 4
entity authorized to participate in the federal 340B Drug Pricing 5
Program under 42 USC 256b(a)(4), as amended from time to time. 6
(b) Not later than April 1, 2025, and annually thereafter, each 340B 7
covered entity shall report to the Health Systems Planning Unit of the 8
Office of Health Strategy, in a form and manner prescribed by the 9
executive director of the Office of Health Strategy, information 10
regarding such entity's participation in the federal 340B Drug Pricing 11
Program. Such report shall include (1) the aggregated acquisition cost 12
for prescription drugs obtained under the program, (2) the aggregated 13
payment amount received for prescription drugs obtained for and 14
dispensed to patients under the program, (3) the aggregated payments 15
made to pharmacies under contract to dispense prescription drugs 16
obtained under the program, (4) the number of claims for prescription 17
drugs described in subdivision (2) of this subsection, (5) if the 340B 18 Substitute Bill No. 241
LCO 2 of 2
covered entity is a hospital licensed pursuant to chapter 368v of the 19
general statutes, the national drug code number for the fifty most 20
frequently dispensed prescription drugs by the hospital under the 21
program, and (6) a description of programs and services offered by the 22
340B covered entity, including, but not limited to, programs and 23
services that support community access to care, that are funded in whole 24
or in part by savings gained through participation in the program and 25
that the 340B covered entity could not continue offering without such 26
savings. The information required to be reported pursuant to this 27
subsection shall (A) be disaggregated by payer mix, including, but not 28
limited to, Medicare, Medicaid and private insurance, as prescribed by 29
the executive director, and (B) include prescription drugs dispensed by 30
outpatient facilities that are child sites listed as reimbursable facilities 31
on a hospital's Medicare cost report. 32
(c) The executive director of the Office of Health Strategy shall post a 33
summary of the aggregate information received by the unit pursuant to 34
the provisions of this section on the Office of Health Strategy's Internet 35
web site. 36
This act shall take effect as follows and shall amend the following
sections:
Section 1 October 1, 2024 New section
PH Joint Favorable Subst.